Amgen Inc. $AMGN Shares Acquired by Perpetual Ltd

Perpetual Ltd boosted its position in Amgen Inc. (NASDAQ:AMGN) by 54.9% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,502 shares of the medical research company’s stock after purchasing an additional 1,595 shares during the period. Perpetual Ltd’s holdings in Amgen were worth $1,474,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of AMGN. Board of the Pension Protection Fund purchased a new stake in shares of Amgen in the 4th quarter worth about $26,000. Howard Hughes Medical Institute purchased a new position in Amgen during the 2nd quarter valued at about $32,000. Olistico Wealth LLC acquired a new position in Amgen during the fourth quarter worth about $33,000. Cloud Capital Management LLC purchased a new stake in shares of Amgen in the third quarter valued at about $34,000. Finally, Saranac Partners Ltd purchased a new stake in shares of Amgen in the third quarter valued at about $37,000. 76.50% of the stock is owned by institutional investors and hedge funds.

Amgen Stock Performance

Shares of AMGN opened at $347.94 on Friday. Amgen Inc. has a 1 year low of $261.43 and a 1 year high of $391.29. The company’s 50 day simple moving average is $363.65 and its 200 day simple moving average is $332.77. The company has a market capitalization of $187.56 billion, a price-to-earnings ratio of 24.45, a PEG ratio of 3.45 and a beta of 0.47. The company has a debt-to-equity ratio of 5.78, a quick ratio of 0.90 and a current ratio of 1.14.

Amgen (NASDAQ:AMGN) last released its earnings results on Tuesday, February 3rd. The medical research company reported $5.29 EPS for the quarter, topping the consensus estimate of $4.76 by $0.53. Amgen had a net margin of 20.98% and a return on equity of 148.37%. The firm had revenue of $9.87 billion during the quarter, compared to analysts’ expectations of $9.46 billion. During the same period in the previous year, the company earned $5.31 EPS. Amgen’s revenue for the quarter was up 8.6% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. On average, sell-side analysts predict that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 5th. Investors of record on Friday, May 15th will be paid a $2.52 dividend. This represents a $10.08 annualized dividend and a yield of 2.9%. The ex-dividend date is Friday, May 15th. Amgen’s dividend payout ratio is presently 70.84%.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on the stock. Argus raised their price objective on shares of Amgen from $360.00 to $400.00 and gave the stock a “buy” rating in a research note on Friday, February 6th. Daiwa Securities Group increased their target price on Amgen from $370.00 to $410.00 and gave the company an “outperform” rating in a report on Tuesday, February 10th. Royal Bank Of Canada raised their price target on Amgen from $335.00 to $360.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 4th. Cantor Fitzgerald boosted their price target on Amgen from $315.00 to $350.00 and gave the stock a “neutral” rating in a report on Wednesday, February 4th. Finally, Jefferies Financial Group started coverage on Amgen in a research report on Tuesday, March 10th. They issued a “hold” rating and a $350.00 price objective on the stock. One research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, thirteen have given a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $354.60.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.